FDA Approves Weight Loss Drug Wegovy for Liver Disease

Contact Your Elected Officials

About 6 percent of American adults have the disease, known as MASH.

The Food and Drug Administration has approved a weight loss drug called Wegovy for a liver disease, the agency announced on Aug. 18.

Wegovy is now approved for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that impacts approximately 6 percent of American adults, the FDA said in a statement.

Updated labeling for Wegovy now lists the treatment.

“The indication for MASH is approved under accelerated approval based on improvement of MASH and fibrosis,” it states. “Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.”

Data supporting the approval came from an interim analysis, at week 72, from a phase 3 double-blind, placebo-controlled trial that’s designed to last for 240 weeks. Patients who received Wegovy were more likely to experience improvement in liver scarring, with no worsening of liver disease.

MASH is also known as nonalcoholic fatty liver disease. The condition can develop in obese people and occurs when fat builds up in one’s liver. That causes inflammation, and can lead to severe problems such as liver cancer unless treated.

Wegovy was already approved for reducing weight in people who are at least 12 years of age “in combination with a reduced calorie diet and increased physical activity.”

It is also cleared for the reduction of cardiovascular events in adults who are oversight or obese, and have cardiovascular disease.

Wegovy is one of several glucagon-like peptide-1 (GLP-1) drugs that have been approved in recent years for weight loss and other purposes. The FDA initially approved Wegovy in 2021 for adults.

Side effects can include thyroid tumors and pancreatic inflammation.

Novo Nordisk, a European manufacturer, makes Wegovy and a similar product, Ozempic, both also known as semaglutide.

“Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide,” Martin Holst Lange, chief scientific officer at Novo Nordisk, said in a statement.

By Zachary Stieber

Read Full Article on TheEpochTimes.com

The Epoch Times
The Epoch Timeshttps://www.theepochtimes.com/
Tired of biased news? The Epoch Times is truthful, factual news that other media outlets don't report. No spin. No agenda. Just honest journalism like it used to be.

Kamala, Please Run Again

Kamala Harris hinted she wants to run for President in 2028, despite poor poll numbers and her loss in 2024. If she runs, the big winners will be the GOP.

Rosie O’Donnell vs. Her Therapist

Rosie O’Donnell's therapist attempted to artfully introduce to her client to the possibility that Rosie's outrage might be performative. It didn’t take.

Hamas’s Stubborn Grip on Arms Signals No Desire for Genuine Peace

Hamas’s rhetoric reflects its founding ideology, prioritizing armed resistance over civilian welfare or diplomatic progress.

Off the radar

In the longstanding and brutal ledger of religious persecution, Nigeria now occupies its own grim chapter with its enduring pogrom against Christians.

The New Jackboots? A Wake-Up Call on Antifa and Fascism

An analysis of whether Antifa truly opposes fascism by comparing its tactics and behavior to historical signs and movements of fascist regimes.

USDA Says SNAP Benefits Will Expire for 41 Million People If Shutdown Persists

More than 41 million Americans will go without food stamps next month if Congress does not vote to reopen the government in time.

Newsom Confirms He’s Considering 2028 Presidential Bid

California Gov. Gavin Newsom said he will seriously consider a presidential campaign after the 2026 midterms are over.

‘Showing Up in Droves’—Gen Z Trades Graduation Caps for Hard Hats

The share of Generation Z workers in the construction labor force more than doubled between 2019 and 2023, according to a recent report.

Dallas Doctor Surrenders License After Texas AG Sues for Prescribing Gender Transition Drugs to Minors

Doctor surrendered her medical license following lawsuit by Texas AG Paxton, accusing her of illegally prescribing gender transition drugs to minors.

Trump Hikes Canada’s Tariffs by 10 Percent for Not Pulling Anti-Tariff Ad Immediately

Trump announced he will increase tariffs on Canada by 10% after ad by provincial government of Ontario misrepresented President Reagan’s speech on tariffs.

Trump Rolls Back Emissions Rules on Copper Smelters

President Trump issued a proclamation aimed at reversing a Biden-era environmental rule that enforced stricter air emission standards on copper smelters.

Donor Gives $130 Million to Cover Shortfall in Troop Pay During Shutdown

Trump announced on Oct. 23 that an anonymous donor sent $130M to cover military pay during the ongoing government shutdown.

‘Frustration’ With Canada Led to Trump Scrapping Talks, Not Just Ontario’s Ad: US Official

President Trump cited Ontario’s TV ad as the reason for halting Canada trade talks, but officials say it stems from rising U.S. frustration with Ottawa.
spot_img

Related Articles

Popular Categories

MAGA Business Central